Neurology Emergency Medicine Cardiology Strong — prospective multicentre derivation and validation
Canadian Syncope Risk Score
Predicts risk of serious adverse events (arrhythmia, death, MI, structural heart disease) within 30 days of syncope presentation to ED. Guides admission vs safe discharge.
References
- Thiruganasambandamoorthy V, et al. Development of the Canadian Syncope Risk Score to predict serious adverse events after emergency department assessment of syncope. CMAJ. 2016;188(12):E289–E298.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Lidocaine IV (Cardiac Arrhythmia) · Antiarrhythmic
- Palivizumab · RSV Prophylaxis — Monthly Monoclonal Antibody (High-Risk Infants)
- Ziprasidone · Atypical Antipsychotic — D2/5-HT2A Antagonist (Low Metabolic Risk)
- Atorvastatin (CKD Cardiovascular Risk) · Cardiovascular Risk in CKD
- Icosapent Ethyl (Omega-3 — Cardiovascular Risk Reduction) · Omega-3 Fatty Acid (Purified EPA — Eicosapentaenoic Acid Ethyl Ester)
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Acute Stroke Management · NICE NG128 / RCP 2023
- TIA Assessment (ABCD2) · NICE NG128 / NICE CG68
- Bacterial Meningitis (Adults) · NICE CG102 / BIA 2016
- Parkinson's Disease Management · NICE NG71 2017
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.